Cadema Corp said it entered a
letter of intent with a national underwriting firm for an
offering of five mln dlrs worth of convertible preferred stock.
    Cadema said it will file a registration statement with the
Securities and Exchange Commission later this month for the
offering. Proceeds will be used to fund clinical trials for the
company's treatments for rheumatoid arthritis and metastatic
bone cancer.
    It also said it increased the size of its board to six from
five members.
 Reuter
&#3;